INT27670

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1982
Last Reported 2011
Negated 1
Speculated 1
Reported most in Body
Documents 122
Total Number 125
Disease Relevance 79.21
Pain Relevance 18.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Ace) peptidase activity (Ace) extracellular space (Ace)
extracellular region (Ace) plasma membrane (Ace)
Anatomy Link Frequency
kidney 8
brain 5
blood 5
lung 4
plasma 3
Ace (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 154 99.96 Very High Very High Very High
opioid receptor 3 99.96 Very High Very High Very High
cINOD 30 99.90 Very High Very High Very High
Morphine 30 99.88 Very High Very High Very High
bradykinin 99 99.74 Very High Very High Very High
tolerance 351 99.52 Very High Very High Very High
beta blocker 30 99.52 Very High Very High Very High
Calcium channel 35 99.42 Very High Very High Very High
agonist 52 99.38 Very High Very High Very High
narcan 49 99.38 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cv Unclassified Under Development 680 99.96 Very High Very High Very High
Hypertension 468 99.84 Very High Very High Very High
Pressure And Volume Under Development 161 99.76 Very High Very High Very High
Proteinuria 399 99.70 Very High Very High Very High
Renal Disease 576 99.66 Very High Very High Very High
Coronary Artery Disease 930 99.56 Very High Very High Very High
Frailty 521 99.56 Very High Very High Very High
Coronary Heart Disease 234 99.56 Very High Very High Very High
Chronic Renal Failure 1039 99.48 Very High Very High Very High
Cancer 574 99.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
All three peptides dose -dependently inhibited ACE activity in vitro except 10(-5) M concentration of BETA-END which increased the lung ACE activity.
Negative_regulation (inhibited) of ACE in lung
1) Confidence 0.57 Published 1986 Journal Pharmacol Res Commun Section Abstract Doc Link 3014570 Disease Relevance 0 Pain Relevance 0.63
Current evidence suggests that inhibition of the RAAS with ACE inhibitors and ARBs stimulates a compensatory increase in plasma renin activity that may negate some of the beneficial effects of these agents.
Negative_regulation (inhibitors) of ACE in plasma
2) Confidence 0.55 Published 2010 Journal Cardiovasc Drugs Ther Section Body Doc Link PMC2887501 Disease Relevance 0.99 Pain Relevance 0
Therefore, direct renin inhibitors have the potential of more comprehensive suppression of the RAAS than ACE inhibitors and ARBs.
Negative_regulation (inhibitors) of ACE
3) Confidence 0.55 Published 2010 Journal Cardiovasc Drugs Ther Section Body Doc Link PMC2887501 Disease Relevance 0.06 Pain Relevance 0.07
Our previous results on the effects of reduced ACE activity could be explained by mechanisms other than angiotensin, such as effects on enkephalin or bradykinin metabolism.
Negative_regulation (reduced) of ACE associated with enkephalin and bradykinin
4) Confidence 0.54 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18037452 Disease Relevance 0.25 Pain Relevance 0.30
In a previous study, a reduction of ACE activity, either in ACE knockout mice or after ACE inhibitor treatment, markedly inhibited the disruption of PPI caused by the dopamine receptor agonist, apomorphine.
Negative_regulation (reduction) of ACE associated with targeted disruption, dopamine receptor and agonist
5) Confidence 0.54 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18037452 Disease Relevance 0.36 Pain Relevance 0.09
Moreover, a circadian phase-dependency in pharmacokinetics has been demonstrated for various cardiovascular active drugs such as beta-blockers, calcium channel blockers, oral nitrates and ACE inhibitors, modified by the pharmaceutical formulation.
Negative_regulation (inhibitors) of ACE associated with beta blocker and calcium channel
6) Confidence 0.52 Published 2006 Journal Pharmacol. Ther. Section Abstract Doc Link 16480770 Disease Relevance 1.21 Pain Relevance 0.53
However, the clinical evidence for ARBs in stable coronary atherosclerosis is more limited than that for ACE inhibitors and has largely been confined to small clinical trials using surrogate markers.
Negative_regulation (inhibitors) of ACE associated with coronary artery disease
7) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.55 Pain Relevance 0
Clinical trials of ACE inhibitors in stable coronary artery disease
Negative_regulation (inhibitors) of ACE in coronary artery associated with coronary artery disease
8) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 1.48 Pain Relevance 0.09
From this meta-analysis, it was found that there was a favorable, modest benefit of ACE inhibitors in patients with CAD and preserved ventricular function on combined cardiovascular outcome used in these studies (Al-Mallah et al 2006).
Negative_regulation (inhibitors) of ACE associated with coronary artery disease
9) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.53 Pain Relevance 0
Thus, while there may be credence to the hypothesis that ACE inhibition may only be beneficial for those at higher cardiovascular risk, it must be noted that there are some limitations to these studies that may weaken any sweeping generalizations about superiority of alternative antihypertensive medications.
Negative_regulation (inhibition) of ACE
10) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.21 Pain Relevance 0.07
Another smaller study on ACE inhibition in stable coronary disease that had negative results was the QUIET trial (Pitt et al 2001).
Negative_regulation (inhibition) of ACE associated with coronary heart disease
11) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.50 Pain Relevance 0.04
In addition to blockade of the RAS system via ACE inhibition, direct blockade of Ang II receptors has proven to be beneficial in patients with systolic dysfunction and myocardial infarction (Pfeffer, McMurray et al 2003; Pfeffer, Swedberg et al 2003).
Negative_regulation (inhibition) of ACE associated with myocardial infarction
12) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.64 Pain Relevance 0
Despite a tremendous amount of heterogeneity between all of these studies, it should also be noted that there has been a meta-analysis of most of the pertinent trials with ACE inhibitors in patients with coronary atherosclerosis (HOPE, EUROPA, PEACE, QUIET, and PART-2 AND CAMELOT).
Negative_regulation (inhibitors) of ACE associated with coronary artery disease
13) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.53 Pain Relevance 0
This heterogeneity has to be taken into account when analyzing these studies and concluding if ACE inhibitors should be used in patients with or at high risk of developing coronary atherosclerosis.


Negative_regulation (inhibitors) of ACE associated with coronary artery disease
14) Confidence 0.51 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350139 Disease Relevance 0.61 Pain Relevance 0
The significant reduction in ACE expression at day 16 following captopril treatment suggests that in addition to the inhibition of ACE activity, captopril also reduces ACE levels, presumably leading to an even greater inhibition of ANG II production.
Negative_regulation (inhibition) of ACE
15) Confidence 0.48 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2860361 Disease Relevance 1.24 Pain Relevance 0
The significant reduction in ACE expression at day 16 following captopril treatment suggests that in addition to the inhibition of ACE activity, captopril also reduces ACE levels, presumably leading to an even greater inhibition of ANG II production.
Negative_regulation (reduces) of ACE
16) Confidence 0.48 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2860361 Disease Relevance 1.17 Pain Relevance 0
Our current results suggest a possible explanation for this, as the increased expression of ACE mRNA (and protein) at this time would require additional, or at least continued, captopril treatment to ensure sustained inhibition of ACE activity.


Negative_regulation (inhibition) of ACE
17) Confidence 0.48 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2860361 Disease Relevance 0.60 Pain Relevance 0
In the 1980s, protective benefits of ACE inhibitors in hypertension were established, regression of left ventricular hypertrophy was demonstrated, and improved ventricular function and survival in mild-to-moderate and severe congestive heart failure was documented.
Negative_regulation (inhibitors) of ACE in heart associated with heart rate under development, left ventricular hypertrophy and hypertension
18) Confidence 0.43 Published 1993 Journal Clin Cardiol Section Abstract Doc Link 8435934 Disease Relevance 0.43 Pain Relevance 0
Despite these apparently diverse "cardiovascular protective" consequences of ACE inhibitor therapy, the mechanism(s) of action of these agents remain to be elucidated.
Negative_regulation (inhibitor) of ACE
19) Confidence 0.43 Published 1993 Journal Clin Cardiol Section Abstract Doc Link 8435934 Disease Relevance 0.74 Pain Relevance 0.11
ACE inhibitors may reduce tolerance to nitrates, reduce angina in some but not all studies, and limit smooth muscle cell proliferation (and perhaps restenosis) induced by experimental balloon angioplasty.
Negative_regulation (inhibitors) of ACE in smooth muscle cell associated with angina, cardiovascular disease and tolerance
20) Confidence 0.43 Published 1993 Journal Clin Cardiol Section Abstract Doc Link 8435934 Disease Relevance 0.97 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox